Breaking

'The first step of our story': Lewis Hamilton fina... Australia and Fiji seal a new mutual defense pact in a push to counter China in the Pacific More than 300 children killed in Sudan war in 6 months, mostly in drone strikes, UNICEF says Deadly clashes break out at prison in Sri Lanka How Mexico's World Cup run brought joy after a year of fear Buckingham Palace says Prince Harry will not stay at palace After Asia’s World Cup stumble, resignations pile up from Seoul to Riyadh Shoot the People review – a powerful portrait of a talented yet controversial photographer Zelenskyy calls for ‘strong decisions’ at Nato summit after Russia kills 11 in overnight strikes on Kyiv – Europe live Quiz: Name every team England have played in a World Cup quarter-final

NEWSREEL

The day, in 30-second reels.

--:--:--

World / Reel

World · Video brief

Repurposed drug may extend survival in aggressive ovarian cancer, trial shows

The Guardian· Apr 25, 2026 · 11:45 AM · 8 views

Exciting news from recent trials shows that relacorilant, a drug originally for Cushing’s syndrome, could extend the survival of ovarian cancer patients. The study revealed a 35% reduction in death risk and an average four-month increase in lifespan for those with platinum-resistant ovarian cancer. Discover more about these promising advancements in cancer treatment. #OvarianCancer #MedicalBreakthrough #CancerResearch #SurvivalRate #HealthNews

Originally reported by The Guardian. Read the full story →

0 Comments

No comments yet. Be the first.

Repurposed drug may extend survival in aggressive ovarian cancer, trial shows

More in World

Deadly clashes break out at prison in Sri Lanka

Buckingham Palace says Prince Harry will not stay at palace

Zelenskyy calls for ‘strong decisions’ at Nato summit after Russia kills 11 in overnight strikes on Kyiv – Europe live

0 Comments